If you enjoy this content, please share it with a colleague
Esaote North America
RELATED CONTENT
October 3, 2014 — Esaote North America announced that its new MyLab Gamma ultrasound system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now available for sale in the United States.
September 8, 2014 — Esaote North America announced its new MyLab Six ultrasound system has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and is now available for sale in the United States.
Esaote is launching MyLab Six, a fast, accurate and highly flexible enhanced ultrasound system at ESC (European Society of Cardiology) in Barcelona, to be held Aug. 30 to Sept. 3. Configured for an extensive range of applications, MyLab Six delivers a premium quality, yet affordable, solution for shared ultrasound services across any busy clinical setting.
Esaote is launching MyLab Gamma, a best-in-class, highly portable “green” cardiovascular ultrasound system at ESC Congress (European Society of Cardiology, Barcelona, Aug. 30-Sept. 3).
More than 55 companies displayed their latest products and services at the American Society of Echocardiography (ASE) 25th Annual Scientific Sessions June 20-24 in Portland, Ore. The meeting is the largest for cardiovascular ultrasound. Highlights from the show floor included:
Cardiac ultrasound technology has advanced to keep up with several trends. These include improved workflow for greater efficiency, expanded use of qualification metrics, expanded use of 3-D echo to speed exam times and improve operator reproducibility, and expanded use of 3-D transesophageal echo (TEE) to aid guidance in the growing area of transcatheter structural heart procedures. Here are a few examples of how the newest technology is addressing these trends.
Argentina’s team doctor, Dr. Alejandro Rolon, is taking no chances with his World Cup squad in Brazil. The complete medical imaging department that has been created at Argentina’s training base includes a dedicated magnetic resonance imaging (MRI) system at the training center itself, and extends to field-level ultrasound scanning of injuries, if required.
Esaote North America received U.S. Food and Drug Administration (FDA) clearance to market and sell its Virtual Navigator fusion imaging technology for ultrasound to U.S. customers.
April 2, 2014 — At the 63rd annual scientific session of the American College of Cardiology (ACC), Esaote premiered its new CrystaLine imaging technology that improves ultrasound’s diagnostic efficiency by enhancing image clarity and providing clinicians the ability to personalize image quality for each patient.
March 5, 2014 — Esaote has launched CrystaLine, a significant evolution of its ultrasound technology that delivers new levels of accuracy, quality, versatility and value. Esaote will showcase the new technology at the 2014 annual meeting of the European Congress of Radiology in Vienna, March 6-10.
October 03, 2014 